Lion Point Capital, LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Lion Point Capital, LP disclosed 35 US equity positions worth $20.9m in its Q2 2026 13F filing. The largest position was CUE at 8.0% of the reported book, followed by PRAX and MLTX. Against the Q1 2026 filing, it opened 1 new position, added to 0 and reduced 0 among the top 35 holdings.
What did Lion Point Capital, LP own in Q2 2026? Top 35 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | CUE CUE BIOPHARMA INC | 8.0% | $1.7m | 52,928 | – | new | |
| 2 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 7.1% | $1.5m | 4,450 | 0% | held |
| 3 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 6.3% | $1.3m | 67,500 | 0% | held |
| 4 | FENC FENNEC PHARMACEUTICALS INC | 5.8% | $1.2m | 112,434 | 0% | held | |
| 5 | RPRX ROYALTY PHARMA PLC | Healthcare | 5.7% | $1.2m | 21,400 | 0% | held |
| 6 | CMPS COMPASS PATHWAYS PLC | Healthcare | 5.4% | $1.1m | 80,000 | 0% | held |
| 7 | MIST MILESTONE PHARMACEUTICALS IN | 5.3% | $1.1m | 820,000 | 0% | held | |
| 8 | BENITEC BIOPHARMA INC | 4.0% | $829.6k | 62,000 | 0% | held | |
| 9 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.8% | $787.0k | 36,000 | 0% | held |
| 10 | BHVN BIOHAVEN LTD | Healthcare | 3.7% | $769.3k | 51,700 | 0% | held |
| 11 | GERN GERON CORP | Healthcare | 3.5% | $739.8k | 578,000 | 0% | held |
| 12 | UNIQURE NV | 3.2% | $677.1k | 14,700 | 0% | held | |
| 13 | ARDX ARDELYX INC | Healthcare | 3.1% | $656.1k | 128,650 | 0% | held |
| 14 | LNTH LANTHEUS HLDGS INC | Healthcare | 2.9% | $610.2k | 5,500 | 0% | held |
| 15 | IRON DISC MEDICINE INC | Healthcare | 2.8% | $592.4k | 8,100 | 0% | held |
| 16 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 2.4% | $512.1k | 28,500 | 0% | held |
| 17 | HUMA HUMACYTE INC | 2.4% | $507.3k | 650,000 | 0% | held | |
| 18 | KURA KURA ONCOLOGY INC | Healthcare | 2.4% | $504.6k | 46,000 | 0% | held |
| 19 | VTRS VIATRIS INC | Healthcare | 2.1% | $439.9k | 27,700 | 0% | held |
| 20 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.9% | $399.8k | 18,000 | 0% | held |
| 21 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.8% | $372.4k | 5,000 | 0% | held |
| 22 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 1.8% | $369.7k | 9,100 | 0% | held |
| 23 | PCRX PACIRA BIOSCIENCES INC | Healthcare | 1.6% | $342.5k | 13,500 | 0% | held |
| 24 | RGNX REGENXBIO INC | Healthcare | 1.5% | $318.7k | 26,600 | 0% | held |
| 25 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 1.4% | $294.1k | 86,000 | 0% | held |
| 26 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.4% | $291.8k | 19,000 | 0% | held |
| 27 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.4% | $283.3k | 10,500 | 0% | held |
| 28 | GHRS GH RESEARCH PLC | Healthcare | 1.3% | $274.2k | 10,200 | 0% | held |
| 29 | SERES THERAPEUTICS INC | 1.2% | $249.1k | 31,570 | 0% | held | |
| 30 | AZTA AZENTA INC | Healthcare | 1.2% | $247.5k | 9,700 | 0% | held |
| 31 | JSPR JASPER THERAPEUTICS INC | 0.9% | $195.8k | 465,000 | 0% | held | |
| 32 | INVA INNOVIVA INC | Healthcare | 0.9% | $186.2k | 8,200 | 0% | held |
| 33 | INNATE PHARMA S A | 0.7% | $149.3k | 81,151 | 0% | held | |
| 34 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.7% | $137.7k | 5,250 | 0% | held |
| 35 | SPRB SPRUCE BIOSCIENCES INC | 0.3% | $54.0k | 1,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.